Neurobiology of impulsive aggression

Borderline Personality Disorder

Volumn , Issue , 2005, Pages 83-102

  Li, Yong ^a   Coccaro, Emil F ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84878354995     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (170)

1. Coccaro EF. Intermittent explosive disorder. Curr Psychiatry Rep 2000; 2: 67-71.
2. Brown GL, Goodwin FK, Ballenger JC, Goyer PF, Major LF. Aggression in human correlates with cerebrospinal fluid amine metabolites. Psychiatry Res 1979; 1:131-139.
3. Brown GL, Ebert MH, Goyer PF, Jimerson DC, Klein WJ, Bunney WE, Goodwin FK. Aggression, suicide, and serotonin: relationships to CSF amine metabolites. Am J Psychiatry 1982; 139:741-746.
4. Virkkunen M, Rawlings R, Tokola, Poland RE, Guidotti A, Nemeroff C, Bissette G, Kalogeras K, Karonen SL, Linnoila M. CSF bio-chemistries, glucose metabolism, and diurnal activity rhythms in alcoholic, violent offenders, fire setters, and healthy volunteers. Arch Gen Psychiatry 1994; 51:20-27.
5. Virkkunen M, Nuutila A, Goodwin FK, Linnoila M. Cerebrospinal fluid monoamine metabolite levels in male arsonists. Arch Gen Psychiatry 1987; 44:241-247.
6. Virkkunen M, DeJong J, Bartko J, Goodwin FK, Linnoila M. Relationship of psychobiological variables to recidivism in violent offenders and impulsive fire setters. Arch Gen Psychiatry 1989; 46:600-603.
7. Linnoila M, Virkkunen M, Scheinin M, Nuutila A, Rimon R, Goodwin FK. Low cerebrospinal fluid 5-hydroxylndolacetic acid concentration differentiates impulsive from nonimpulsive violent behavior. Life Sci 1983; 33:2609-2614.
8. Limson R, Goldman D, Roy A, Lamparski D, Ravitz B, Adinoff B, Linnoila M. Personality and cerebrospinal fluid monoamine metabolites in alcoholics and controls. Arch Gen Psychiatry 1991; 48:437-441.
9. Kruesi MJP, Rapoport JL, Hamberger S, Hibbs E, Potter WZ, Lenane M, Brown GL. Cerebrospinal fluid metabolites, aggression, and impulsivity in disruptive behavior disorders of children and adolescents. Arch Gen Psychiatry 1990; 47:419-462.
10. Higley JD, Mehlman PT, Taub DM, Higley SB, Suomi SJ, Vickers JH, Linnoila M. Cerebrospinal fluid monoamine and adrenal correlates of aggression in free-ranging rhesus monkeys. Arch Gen Psychiatry 1992; 49:436-441.
11. Westergaard GC, Suomi SJ, Higley JD, Mehlman PT. CSF 5-HIAA and aggression in female macaque monkeys: species and interindividual differences. Psychopharmacology 1999; 146:440-444.
12. Gardner DL, Lucas PB, Cowdry RW. CSF metabolites in borderline personality disorder compared with normal controls. Biol Psychiatry 1990; 28: 247-254.
13. Castellanos FX, Elia J, Kreusi MJP, Gulotta CS, Mefford IN, Potter WZ, Ritchie GF, Rapoport JL. Cerebrospinal fluid monoamine metabolites in boys with attention deficit hyperactivity disorder. Psychiatry Res 1994; 52: 305-316.
14. Moller SE, Mortensen EL, Breum L, Alling C, Larsen OG, Boge-Rasmussen T, Jensen C, Bennicke K. Aggression and personality: association with amino acids and monoamine metabolites. Psychol Med 1996; 26:323-331.
15. Coccaro EF, Kavoussi RJ, Hauger RL. Serotonin function and antiaggressive responses to fluoxetine: a pilot study. Biol Psychiatry 1997; 42:546-552.
16. Coccaro EF, Kavoussi RJ, Trestman RL, Gabriel SM, Cooper TB, Siever LJ. Serotonin function in human subjects: intercorrelations among central 5-HT indices and aggressiveness. Psychiatry Res 1997; 73(1-2):1-14.
17. Roggenbach J, Muller-Oerlinghausen, Franke L. Suicidality, impulsivity and aggression-is there a link to 5HIAA concentration in the cerebral spinal fluid? Psychiatry Res 2002; 113:193-206.
18. Coccaro EF, Kavoussi RJ, Cooper TB, Hauger RL. Central serotonin activity and aggression: inverse relationship with prolactin response to d-fenfluramine, but not CSF 5-HIAA concentration, in human subjects. Am J Psychiatry 1997; 154(10):1430-1435.
19. Coccaro EF, Siever LJ, Klar HM, Maurer G, Cochrane K, Mohs RC, Davis KL. Serotonergic studies in affective and personality disorder: correlates with suicidal and impulsive aggressive behavior. Arch Gen Psychiatry 1989; 46: 587-599.
20. Coccaro EF, Kavoussi RJ, Oakes M, Cooper TB, Hauger R. Amesergide completely blocks the prolactin response to d-fenfluramine in healthy male subjects. Psychopharmacology 1996; 126:24-30.
21. Park SBG, Cowen PJ. Effect of pindolol on the prolactin response to d-fenfluramine. Psychopharmacology 1995; 118:471-474.
22. Coccaro EF, Kavoussi RJ, Cooper TB, Hauger R. 5-HT-3 receptor antagonism by ondansetron does not attenuate the prolactin response to d-fenfluramine challenge in healthy male subjects. Psychopharmacology 1996; 127:108-112.
23. Coccaro EF, Kavoussi RJ, Hauger RL. Physiologic responses to d-fenfluramine and ipsapirone challenge correlate with indices of aggression in males with personality disorder. Int Clin Psychopharmacol 1995; 10:177-180.
24. Moeller FG, Allen T, Cherek DR, Dougherty DM, Lane S, Swann AC. Ipsa-pirone neuroendocrine challenge: relationship to aggression as measured in the human laboratory. Psychiatry Res 1998; 18:31-38.
25. New AS, Trestman RL, Mitroupoulou V, Benishay DS, Coccaro E, Silverman J, Siever LJ. Serotonergic function and self-injurious behavior in personality disorder patients. Psychiatry Res 1997; 69:17-26.
26. Moss HB, Yao JK, Panzak GL. Serotonergic responsivity and behavioral dimensions in antisocial personality disorder with substance abuse. Biol Psychiatry 1990; 28:325-338.
27. Handlesman L, Holloway K, Kahn RS, Sturiano C, Rinaldi PJ, Bernstein DP, Siever L, Gabriel S, Cooper TB. Hostility is associated with a low prolactin response to meta-chlorophenylpiperazine in abstinent alcoholics. Alcohol Clin Exp Res 1996; 20:824-829.
28. Fishbein DH, Lozovsky D, Jaffe JH. Impulsivity, aggression, and neuroendo-crine responses to serotonergic stimulation in substance abusers. Biol Psychiatry 1989; 25:1049-1066.
29. Bernstein DP, Handlesman L. The neurobiology of substance abuse and personality disorders. In: Ratey JJ, ed. Neuropsychiatry of Behavior Disorders. UK: Blackwell Scientific Publications, 1995:120-148.
30. Lopez-Ibor JJ, Lana F, Saiz Ruiz J. Conductas autoliticas impulsivas y sero-tonina. Actas Luso-Esp Neurol Psiquiatr 1990; 18:316-325.
31. O'Keane V, Moloney E, O'Neill H. Blunted prolactin responses to d-fenfluramine in sociopahty: evidence of subsensitivity of central serotonergic function. Br J Psychiatry 1992; 160:643-646.
32. Manuck SB, Flory JD, McCaffery JM, Matthews KA, Mann JJ, Muldoon MF. Aggression, impulsivity, and central nervous system serootnergic responsivity in a nonpatient sample. Neurpsychopharmacology 1998; 19: 287-299.
33. Halperin JM, Sharma V, Siever LJ, Schwartz ST, Matier K, Wornell G, Newcorn JH. Serotonergic function in aggressive and nonaggressive boys with attention deficit hyperactivity disorder. Am J Psychiatry 1994; 151:243-248.
34. Pine DS, Coplan JD, Wasserman GA, Miller LS, Fried JE, Davies M, Cooper TB, Greenhill L, Shaffer D, Parsons B. Neuroendocrine response to d, l-fenfluraminje challenge in boys: associations with aggressive behavior and adverse rearing. Arch Gen Psychiatry 1997; 54:839-846.
35. Halperin JM, Schulz KP, McKay KE, Sharma V, Newcorn JH. Familial correlates of central serotonin function in children with disruptive behavior disorders. Psychiatry Res 2003; 119:205-216.
36. Taylor SP. Aggressive behavior and physiological arousal as a function of provocation and the tendency to inhibit aggression. J Pers 1967; 35:297-310.
37. Cherek DR, Moeller G, Schnapp W, Dougherty DM. Studies of violent and non-violent male parolees: I. Laboratory and psychometric measurements of aggression. Biol Psychiatry 1997; 41:514-522.
38. Coccaro EF, Kavoussi RJ, Sheline YI, Lish JD, Csernansky JG. Impulsive aggression in personality disorder: correlates with 3-H-paroxetine binding in the platelet. Arch Gen Psychiatry 1996; 53:531-536.
39. Pihl RO, Young S, Harden P, Plotnick S, Chamberlain B, Ervin FR. Acute effect of altered tryptophan levels and alcohol on aggression in normal human males. Psychopharmacology 1995; 119:353-360.
40. Cleare AJ, Bond AJ. The effect of tryptophan depletion and enhancement on subjective and behavioural aggression in normal male subjects. Psychophar-macology 1995; 118:72-81.
41. Moeller FG, Dougherty DM, Swann, Collins D, Davis CM, Cherek DR. Tryptophan depletion and aggressive responding in healthy males. Psycho-pharmacology 1996; 126:97-103.
42. Dougherty DM, Bjork JM, Marsh DM, Moeller FG. Influence of trait hostility on tryptophan depletion-induced laboratory aggression. Psychiatry Res 1999; 88:227-232.
43. Cherek DR, Spiga R, Creson DL. Acute effects of eltoprazine on aggressive and point-maintained responding of normal male participants: phase I study. Exp Clinical Psychopharmacol 1995; 3:287-293.
44. Evenden JL, Ryan CN. The pharmacology of impulsive behavior in rats: the effects of drugs on response choice with varying delays of reinforcement. Psy-chopharmacology 1996; 128:161-170.
45. Evenden JL. The pharmacology of impulsive behavior in rats 2: the effects of amphetamine, halpperidol, imipramine, chlordiazepoxide and other drugs on fixed consecutive number schedules. Psychopharmacology 1998; 138:283-294.
46. Evenden JL. The pharmacology of impulsive behavior in rats 3: the effects of amphetamine, halpperidol, imipramine, chlordiazepoxide and other drugs on fixed consecutive number schedules. Psychopharmacology 1998; 138:295-304.
47. Matsumoto K, Ojima K, Watanabe H. Noradrenergic denervation attenuates desipramine enhancement of aggressive behavior in isolated mice. Pharmacol Biochem Behav 1995; 50:481-484.
48. Coccaro EF. Neurotransmitter correlates of impulsive aggression in humans. Ann NY Acad Sci 1996; 794:82-89.
49. Virkkunen M, Rawlings R, Tokola R, Poland RE, Guidotti A, Nemeroff C, Bissette G, Kalogeras K, Karonen SL, Linnoila M. CSF biochemistries, glucose metabolism, and diurnal activity rhythms in alcoholic, violent offenders, fire setters, and healthy volunteers. Arch Gen Psychiatry 1994; 51:20-27.
50. Coccaro EF, Lee R, McCloskey M. Norepinephrine function in personality disorder: plasma free MHPG correlates inversely with life history of aggression. CNS Spectr 2003; 8:731-736.
51. Coccaro EF, Lawrence T, Trestman R, Gabriel S, Klar HM, Siever L. Growth hormone responses to intravenous clonidine challenge correlates with beha-vioral irritability in psychiatric patients and in healthy volunteers. Psychiatry Res 1991; 39:129-139.
52. Kuikka JT, Tiihonen J, Bergstrom KA, Karhu J, Rasanen P, Eronen M. Abnormal structure of human striatal dopamine re-uptake sites in habitually violent alcoholic offenders: a fractal analysis. Neurosci Lett 1998; 253: 195-197.
53. Lion JR, Ascarate C, Koepke H. Parasoxical rage reactions during psychotropic medication. Dis Nerv Syst 1975; 36:557-558.
54. Itil TM, Seaman P. Drug treatment of human aggression. Prog Neuropsycho-pharmacol 1978; 2:659.
55. Sheard MH. Clinical pharmacology of aggressive behavior. Clin Neurophar-macol 1984; 7:173-183.
56. Dimascio A. The effects of benzodiazepines on aggression: reduced or increased. Psychopharmacologia 1973; 30:95-102.
57. Bond AJ, Curran HV, Bruce MS, O'Sullivan G, Shine P. Behavioral aggression in panic disorder after 8 weeks treatment with alprazolam. J Affective Disord 1995; 35:17-123.
58. Weisman AM, Berman ME, Taylor SP. Effects of clorazepate, diazepam, and oxazepam on a laboratory measurement of aggression in men. Int Clin Psy-chopharmacol 1998; 13:183-188.
59. Bond A, Lader M. Differential effects of oxazepam and lorazepam on aggressive responding. Psychopharmacology 1988; 95:369-373.
60. Cherek DR, Spiga R, Egli M. Effects of response requirement and alcohol on human aggressive responding. J Exp Anal Behav 1992; 58:577-587.
61. Grant KA. Emerging neurochemical concepts in the actions of ethanol at ligand-gated ion channels. Behav Pharmacol 1994; 5:383-404.
62. Grobin AC, Mathews DB, Devaud LL, Morrow AL. The role of GABAa receptors in the acute and chronic effects of ethanol. Psychopharmacology 1998; 139:2-19.
63. Weerts EM, Tornatzky W, Miczek KA. Prevention of the proaggressive effects of alcohol by benzodiazepine receptor antagonists in rats and squirrel monkeys. Psychopharmacology 1993; 111:144-152.
64. Weerts EM, Miczek KA. Primate vocalizations during social separation and aggression: effects of alcohol and benzodiazepines. Psychopharmacology 1996; 127:255-264.
65. Miczek KA, Fish EW, de Bold JF, de Almeida RMM. Social and neural determinants of aggressive behavior: pharmacotherapeutic targets at serotonin, dopamine, and GABA systems. Psychopharmacology 2002; 163:434-458.
66. Miczek KA, Fish EW, de Bold JF. Neurosteroids, GABAa receptors, and escalated aggressive behavior. Horm Behav 2003; 44:242-257.
67. Archer J. The influence of testosterone on human aggression. Br J Psychology 1991; 82:1-28.
68. Rubinow DR, Schmidt PJ. Androgens, brain, and behavior. Am J Psychiatry 1996; 153:974-984.
69. Sanchez ME, Fano L, Ahedo J, Cardas J, Brain PF, Azpiroz A. Rating testosterone levels and free play social behavior in male and female preschool children. Psychoendocrinology 2000; 8:773-783.
70. Dabbs JM, Carr TS, Frady RI, Riad JK. Testosterone, crime, and misbeha-vior among 692 male prison inmates. Person Individ Dif 1995; 18:627-633.
71. Banks T, Dabbs JM. Salivary testosterone and cortisol in a delinquent and violent urban subculture. J Soc Psychol 1996; 136:49-56.
72. Bergman B, Brismar B. Characteristics of imprisoned wife-beaters. Forensic Sci Int 1994; 65:157-167.
73. Gerra G, Avanzini P, Zaimovic A, Fertonani G, Caccavari R, Delsignore R, Gardini F, Talarico E, Lecchini R, Maestri D, Brambilla F. Neurotransmitter and endocrine modulation of aggressive behavior and its components in normal humans. Behav Brain Res 1996; 81:19-24.
74. Gerra G, Zaimovic A, Avanzini P, Chittolini B, Giucastro G, Caccavari R, Palladino M, Maestri D, Monica C, Delsignore R, Brambilla F. Neurotransmitter-neuroendocrine responses to experimentally induced aggression in humans: influence of personality. Variable Psychiatry Res 1997; 66:33-43.
75. Kouri EM, Lukas SE, Pope HG Jr, Oliva PS. Increased aggressive responding in male volunteers following the administration of gradually increasing doses of testosterone cypionate. Drug Alcohol Depend 1995; 40:73-79.
76. Pope HG Jr, Kouri EM, Hudson JI. Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: a randomized controlled trial. Arch Gen Psychiatry 2000; 57:133-140.
77. Birger M, Swartz M, Cohen D, Alesh Y, Grishpan C, Kotelr M. Aggression: the testosterone-serotonin link. Isr Med Assoc J 2003; 5:653-658.
78. O'Connor DB, Archer J, Wu FC. Effects of testosterone on mood, aggression, and sexual behavior in young men: a double-blind, placebo-controlled, crossover study. J Clin Endocrinol Metabolism 2004; 89:2837-2845.
79. Pinna G, Dong E, Matsumoto K, Costa E, Guidotti A. In socially isolated mice, the reversal of brain allopregnanolone down-regulation mediates the anti-aggressive action of fluoxetine. Pro Nat Acad Sci 2003; 100: 2035-2040.
80. Coccaro EF, Kavoussi RJ, Hauger RL, Cooper TB, Ferris CF. Cerebrospinal fluid vasopressin: correlates with aggression and serotonin function in personality disordered subjects. Arch Gen Psychiatry 1998; 55:708-714.
81. Coid J, Allolio B, Rees LH. Raised plasma metenkephalin in patients who habitually mutilate themselves. Lancet 1983; 2:545-546.
82. Spiga R, Cherek DR, Roache JD, Cowan KA. The effects of codeine on human aggressive responding. Int Clin Psychopharmacol 1990; 5:195-204.
83. Berman M, Taylor S, Marged B. Morphine and human aggression. Addict Behav 1993; 18:263-268.
84. Sandman CA, Barron JL, Colman H. An orally administered opiate blocker, naltrexone, attenuates self-injurious behavior. Am J Ment Retard 1990; 95: 93-102.
85. Sandman CA, Hedrick W, Taylor DV, Marion SD, Touchette P, Barron JL, Martinezzi V, Steinberg RM, Crinella FM. Long-term effects of naltrexone on self-injurious behavior. Am J Ment Retard 2000; 105:103-117.
86. Virkkunen M. Serum cholesterol in levels in homicidal offenders. A low cholesterol level is connected with a habitually violent tendency under the influence of alcohol. Neuropsychobiology 1983; 10:65-69.
87. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Maenpaa H, Malkonen M, Hanttari M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjoblom T, Nikkia EA. Helsinki heart study: primary prevention trial with gemfibrozil in middle-aged men with syslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-1245.
88. Muldoon MF, Rossouw JE, Manuck SB, Glueck CJ, Kaplan JR, Kaufmann PG. Low or lowered cholesterol and risk of death from suicide and trauma. Metabolism 1993; 42(suppl 1):45-56.
89. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentration and mortality: a quantitative review of primary prevention trials. Br Med J 1990; 301:309-314.
90. Neaton JD, Blackburn H, Jacobs D, Kuller L, Lee DJ, Sherwin R, Shih J, Stamler J, Wentworth D. Serum cholesterol level and mortality findings for men screened in the multiple risk factor intervention Trial Research Group. Arch Intern Med 1992; 152:1490-1500.
91. Maes M, Smith R, Christophe A, Vandoolaeghe E, Van Gastel A, Neels H, Demedts P, Wauters A, Meltzer HY. Lower serum high density lipoprotein cholesterol (HDL-C) in major depression and in depressed men with serious suicidal attempts: relationship with immune-inflammatory markers. Acta Psy-chiatr Scand 1997; 95:212-221.
92. Markovitz JH, Smith D, Raczynski JM, Oberman A, Williams OD, Knox S, Jacobs DR Jr. Lack of relations of hostility, negative affect and high risk beha-vior with low plasma lipid levels in the Coronary Artery Risk Development in Young Adults Study. Arch Intern Med 1997; 157:1953-1959.
93. Goier JA, Marzuk PM, Leon AC, Weiner C, Tardiff K. Low serum cholesterol and attempted suicide. Am J Psychiatry 1993; 152:419-423.
94. Zureik M, Courbon D, Ducimetiere P. Serum cholesterol concentration and death from suicide in men: Paris prospective study I. B Med J 1996; 313:649-651.
95. Maes M, Sharpe P, D'Hondt P, Peeters D, Wauters A, Neels H, Verkerk R. Biochemical metabolic and immune correlates of seasonal variation in violent suicide: a chronoepidemiologic study. European Psychiatry 1996; 11:21-33.
96. Kunugi H, Takei N, Aoki H, Nanko S. Low serum cholesterol in suicide attempters. Biol Psychiatry 1997; 41:196-200.
97. Zanarini MC, Frankenburg FR. Omega-3 fatty acid treatment of women with borderline personality disorder. Am J Psychiatry 2003; 160:167-169.
98. Brunner HG, Nelen M, Breakefeld XO, Ropers HH, vanOost BA. Abnormal behavior associated with a point mutation in the structural gene for monoa-mine oxidase A. Science 1995; 262:578-580.
99. Manuck SB, Flory JD, Ferrell RE, Mann JJ, Muldoon M. A regulatory polymorphism of the monoamine oxidase-A gene may be associated with variability in aggression, impulsivity, and central nervous system serotonergic responsivity. Psychiatry Research 2000; 95:9-23.
100. Caspi A, McClay J, Moffitt TE, Mill J, Martin J, Craig IW, Taylor A, Poulton R. Role of genotype in the cycle of violence in maltreated children. Science 2002; 297:851-854.
101. Nielson DA, Goldman D, Virkkunen M, Tokola R, Rawlings R, Linnoila M. Suicidality and 5-hydroxyindolacetic acid concentration associated with a tryptophan hydoxylase polymorphism. Arch Gen Psychiatry 1994; 51:34-38.
102. Nielson DA, Virkkunen M, Lappalainen J, Eggert M, Brown GL, Long JC, Goldman D, Linnoila M. A tryptophan hydroxylase gene marker for suicidality and alcoholism. Arch Gen Psychiatry 1998; 55:593-602.
103. New AS, Gelernter J, Yovell Y, Trestman RL, Nielson DA, Silverman J, Mitroupolou V, Siever LJ. Tryptophan hydroxylase genotype is associated with impulsive aggression measures. Am J Med Genet 1998; 81:13-17.
104. Staner L, Uyanik G, Correa H, Tremeau F, Monreal J, Crocq MA, Stefos G, Morris-Rosendahl DJ, Macher JP. A dimensional impulsiveaggressive phenotype is associated with the A218C polymorphism of the tryptophan hydroxy-lase gene: a pilot study in well-characterized impulsive Inpatients. Am J Med Genet 2002; 114:553-557.
105. Kavoussi R, Armstead P, Coccaro E. The neurobiology of impulsive aggression. Psychiatr Clin North Am 1997; 20:395-403.
106. Davidson RJ, Putnam KM, Larson CL. Dysfunction in the neural circuitry of emotion regulation: a possible prelude to violence. Science 2000; 289:591-594.
107. Brower MC, Price BH. Neuropsychiatry of frontal lobe dysfunction in violent and criminal behavior: a critical review. J Neurol Neurosurg Psychiatry 2001; 71:720-726.
108. Damasio H, Grabowski T, Frank R, Galaburda AM, Damasio AR. The return of Phineas Gage: clues about the brain from the skull of a famous patient. Science 1994; 264:1102-1105.
109. Brickner RM. An interpretation of frontal lobe function based upon the study of a case of partial bilateral lobectomy. Res Nerv Ment Dis 1934; 13:259-351.
110. Grafman J, Schwab K, Warden D, Pridgen A, Brown H, Salazar A. Frontal lobe injuries, violence, and aggression: a report of the vietnam head injury study. Neurology 1996:1231-1238.
111. Weiger WA, Bear DM. An approach to the neurology of aggression. J Psy-chiatr Res 1988; 22:85-98.
112. Anderson SW, Bechara A, Damasio H, Tranel D, Damasio AR. Impairment of social and moral behavior related to early damage in human prefrontal cortex. Nat Neurosci 1999; 2:1032-1037.
113. Raine A, Lencz T, Bihrle S, LaCasse L, Colletti P. Reduced prefrontal gray matter volume and reduced autonomic activity in antisocial personality disorder. Arch Gen Psychiatry 2000; 57:119-127.
114. Woermann FG, Tebartz van Elst L, Koepp MJ, Free SL, Thompson PJ, Trimble MR, Duncan JS. Reduction of frontal neocortical grey matter associated with affective aggression in patients with temporal lobe epilepsy: an objective voxel by voxel analysis of automatically segmented MRI. J Neurol Neurosurg Psychiatry 2000; 68:162-169.
115. Blair RJR, Morris JS, Frith CD, Perrett DI, Dolan RJ. Dissociable neural responses to facial expressions of sadness and anger. Brain 1999; 122:883-893.
116. Dougherty DD, Shin LM, Alpert NM, Pitman RK, Orr SP, Lasko M, Macklin ML, Fischman AJ, Rauch SL. Anger in healthy men: a PET study using script-driven imagery. Biol Psychiatry 1999; 46:466-472.
117. Kimbrell TA, George MS, Parekh PI, Ketter TA, Podell DM, Danielson AL, Repella JD, Benson BE, Willis MW, Herscovitch P, Post RM. Regional brain activity during transiently self-induced anxiety and anger in healthy adults. Biol Psychiatry 1999; 46:454-465.
118. Damasio AR, Grabowski TJ, Bechara A, Damasio H, Ponto LLB, Parvizi J, Hichwa RD. Subcortical and cortical brain activity during the feelings of self-generated emotions. Nat Neurosci 2000; 3:1049-1056.
119. Volkow ND, Tancredi LR. Neural substrates of violent behavior: a preliminary study with positron emission tomography. Br J Psychiatry 1987; 151: 668-673.
120. Volkow ND, Tancredi LR, Grant C, Gillespie H, Valentine A, Mullani N, Wang GJ, Hollister L. Brain glucose metabolism in violent psychiatric patients: a preliminary study. Psychiatry Res 1995; 61:243-253.
121. Raine A, Buchsbaum M, Stanley J, Lottenberg S, Abel L, Stoddard J. Selective reductions in prefrontal glucose metabolism in murderers. Biol Psychiatry 1994; 36:365-373.
122. Raine A, Phil D, Stoddard J, Bihrle S, Buchsbaum M. Prefrontal glucose deficits in murderers lacking psychosocial deprivation. Neuropsychiatry Neurop-sychol Behav Neurol 1998; 11:1-7.
123. Soderstrom H, Tullberg M, Wikkelso C, Ekholm S, Forsman A. Reduced regional cerebral blood flow in non-psychotic violent offenders. Psychiatry Res 2000; 98:29-41.
124. Soderstrom H, Hultin L, Tullberg M, Wikkelso C, Ekholm S, Forsman A. Reduced frontotemporal perfusion in psychopathic personality. Psychiatry Res 2002; 114:81-94.
125. Soloff PH, Meltzer CC, Becker C, Greer P, Kelly TM, Constantine D. Impul-sivity and prefrontal hypometabolism in borderline personality disorder. Psychiatry Res 2003; 123:153-163.
126. Arango V, Ernsberger P, Marzuk PM, Chen JS, Tierney H, Stanley M, Reis DJ, Mann JJ. Autoradiographic demonstration of increased serotonin 5-HT2 receptors and beta-adrenergic receptor binding sites in the brain of suicide victims. Arch Gen Psychiatry 1990; 47:1038-1047.
127. Mann J, Malone K, Diehl D, Perel J, Nichols TE, Mintun MA. Positron emission tomographic imaging of serotonin activation effects on prefrontal cortex in healthy volunteers. J Cereb Blood Flow Metab 1996; 16:418-426.
128. Siever LJ, Buchsbaum MS, New AS, Spiegel-Cohen J, Wei T, Hazlett EA, Sevin E, Nunn M, Mitropoulou V. d,I-Fenfluramine response in impulsive personality disorder assessed with [18F]fluorodeoxyglucose positron emission tomography. Neuropsychopharmacology 1999; 20:413-423.
129. Soloff PH, Meltzer CC, Greer PJ, Constantine D, Kelly TM. A fenfluramine-activated FDG-PET study of borderline personality disorder. Biol Psychiatry 2000; 47:540-547.
130. Siever LJ, Buchsbaum MS, New AS, Hazlett EA, Grossman R, Reynolds D. Serotonergic responsiveness in impulsive/aggressive personality disorders. Biol Psychiatry 2000; 47:1S-173S.
131. New AS, Hazlett EA, Buchsbaum MS, Goodman M, Reynolds D, Mitropoulou V, Sprung L, Shaw RB, Koenigsberg H, Platholi J, Silverman J, Siever LJ. Blunted prefrontal cortical 18fluorodeoxyglucose positron emission tomography response to meta-chlorophenylpiperazine in impulsive aggression. Arch Gen Psychiatry 2002; 59:621-629.
132. Mark VH, Sweet W, Ervin FR. Deep temporal lobe stimulation and destructive lesions in episodically violent temporal lobe epileptics. Neural bases of violence and aggression 1975:379-391.
133. Patrick CJ, Bradley MM, Lang PJ. Emotion in the criminal psychopath: startle reflex modulation. J Abnorm Psychol 1993; 102:82-92.
134. Angrilli A, Mauri A, Palomba D, Flor H, Birhaumer N, Sartori G, di Paola F. Startle reflex and emotion modulation impairment after a right amygdala lesion. Brain 1996; 119:1991-2000.
135. Bechara A, Tranel D, Damasio H, Adolphs R, Rockland C, Damasio AR. Double dissociation of conditioning and declarative knowledge relative to the amygdala and hippocampus in humans. Science 1995; 269:1115-1118.
136. LaBar KS, LeDoux JE, Spencer DD, Phelps EA. Impaired fear conditioned behavior following unilateral temporal lobectomy in humans. J Neurosci 1995; 15:6846-6855.
137. Adolphs R, Tranel D, Young AW, Calder AJ, Phelps EA, Anderson AK, Lee GP, Damasio AR. Recognition of facial emotion in nine individuals with bilateral amygdala damage. Neuropsychologia 1999; 37:1111-1117.
138. Fine C, Blair RJR. The cognitive and emotional effects of amygdala damage. Neurocase 2000; 6:435-450.
139. Stevens D, Charman T, Blair RJR. Recognition of emotion in expression and vocal tones in children with psychopathic tendencies. J Genet Psychol 2001; 162:201-211.
140. Milad MR, Quirk GJ. Neurons in medial prefrontal cortex signal memory for fear extinction. Nature 2002; 420:70-74.
141. Tebartz van Elst L, Woermann F, Lemieux L, Thompson PJ, Trimble MR. Affective aggression in patients with temporal lobe epilepsy: a quantitative magnetic resonance study of the amygdala. Brain 2000; 123:234-243.
142. Veit R, Flor H, Erb M, Hermann C, Lotze M, Grodd W, Birbaumer N. Brain circuits involved in emotional learning in antisocial behavior and social phobia in humans. Neurosci Lett 2002; 328:233-236.
143. Sheard M, Manini J, Bridges C, Wapner A. The effect of lithium on impulsive aggressive behavior in man. Am J Psychiatry 1976; 133:1409-1413.
144. Campbell M, Adams PB, Small AM, Kafantaris V, Silva RR, Shell J, Perry R, Overall JE. Lithium in hospitalized aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry 1995; 34:445-453.
145. Craft M, Ismail IA, Krishnamurti D, Mathews J, Regan A, Seth RV, North PM. Lithium in the treatment of aggression in mentally handicapped patients. A double-blind trial. Br J Psychiatry 1987; 150:685-689.
146. Salzman C, Wolfson AN, Schatzberg A, Looper J, Henke R, Albanese M, Schwartz J, Miyawaki E. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacology 1995; 15:23-29.
147. Coccaro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive behavior in personality disordered subjects. Arch Gen Psychiatry 1997; 54:1081-1088.
148. Fava M, Rosenbaum JF, Pava JA, McCarthy MK, Steingard RJ, Bouffides E. Anger attacks in unipolar depression, part 1: clinical correlates and response to fluoxetine treatment. Am J Psychiatry 1993; 150:1158-1163.
149. McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 1996; 53:1001-1008.
150. Coccaro EF, Kavoussi RJ, Cooper TB, Hauger RL. Central serotonin and aggression: inverse relationship with prolactin response to d-fenfluramine, but not with CSF 5-HIAA concentration in human subjects. Am J Psychiatry 1997; 154:1430-1435.
151. Hollander E, Tracy KA, Swann AC, Coccaro EF, McElroy SL, Wozniak P, Sommerville KW, Nemeroff CB. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharma-cology 2003; 28:1186-1197.
152. Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind, placebo-controlled pilot study. J Clin Psychiatry 2002; 63:442-446.
153. Donovan SJ, Steward JW, Nunes EV, Quitkin FM, Parides M, Daniel W, Susser E, Klein DF. Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled, cross-over design. Am J Psychiatry 2000; 157:818-820.
154. Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder: Alprazolam, Carbamazepine, Trifluroperazine, and Trancypromine. Arch Gen Psychiatry 1998; 45:111-119.
155. Cueva JE, Overall JE, Small AM, Armenteros JL, Perry R, Campbell M. Carba-mazepine in aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry 1996; 35:480-490.
156. Buckley P, Bartell J, Donenwirth K, Lee S, Torigoe F, Schulz SC. Violence and schizophrenia: clozapine as a specific antiaggressive agent. Bull Am Acad Psychiatry Law 1995; 23:607-611.
157. Rabinowitz J, Avnon M, Rosenberg V. Effect of clozapine on physical and verbal aggression. Schizophr Res 1996; 22:249-255.
158. Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, Lee E, Lyons B, Grossman F. A randomized placebo-controlled trial of risperi-done for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003; 64:134-143.
159. Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry 2001; 62:849-854.
160. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL, Risperidone Disruptive Behavior Study Group. Double-blind, placebo-controlled study of ris-peridone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 2002; 159:1337-1346.
161. Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A, Risperidone Conduct Study Group. Effects of risperidone on conduct and disruptive beha-vior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 2002; 41:1026-1036.
162. Volavka J, Czobor P, Nolan K, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Cooper TB, Lieberman JA. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risper-idone, or haloperidol. J Clin Psychopharmacol 2004; 24:225-228.
163. Greendyke RM, Kanter DR. Therapeutic effects of pindolol on behavioural disturbances associated with organic brain disease: a double-blind study. J Clin Psychiatry 1986; 47:423-426.
164. Greendyke RM, Kanter DR, Schuster DB, Verstreate S, Wootton J. Propra-nolol treatment of assaultive patients with organic brain disease: a double- blind cross-over, placebo-controlled study. J Nerv Ment Dis 1986; 174: 290-294.
165. Shankle WR, Nielson KA, Cotman CW. Low-dose propranolol reduces aggression and agitation resembling that associated with orbitofrontal dysfunction in elderly demented patients. Alzheimer Dis Assoc Disord 1995; 9:233-237.
166. Ratey JJ, Sorgi P, O'Driscoll GA, Sands S, Daehler ML, Fletcher JR, Kadish W, Spruiell G, Polakoff S, Lindem KJ, Bemporad JR, Richardson L, Rosenfeld B. Nadolol to treat aggression and psychiatric symptomatology in chronic psychiatric inpatients: a double-blind, placebo-controlled study. J Clin Psychiatry 1992; 53:41-46.
167. Caspi N, Modai I, Barak P, Waisbourd A, Zbarsky H, Hirschmann S, Ritsner M. Pindolol augmentation in aggressive schizophrenic patients: a double-blind crossover randomized study. Int Clin Psychopharmacol 2001; 16:111-115.
168. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention deficit/hyperactivity disorder. Arch Gen Psychiatry 1999; 56:1073-1086.
169. Conner DF, Barkley RA, Davis HT. A pilot study of methylphenidate, cloni-dine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin Pediatr 2000; 39:15-25.
170. Bahrke MS, Yesalis CE III, Wright JE. Psychological and behavioral effects of endogenous testosterone and anabolic-androgenic steroids: an update. Sports Med 1996; 22:367-390.